Development of Escitalopram Genomic Device by Using Candidate Gene Approach and Genome-Wide Scanning.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escitalopram (Primary)
Indications Depressive disorders
Focus Therapeutic Use

Most Recent Events

30 Dec 2015 According to ClinicalTrials.gov record, the treatment table has been amended to include 2 arms.
30 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
04 Jun 2015 Planned End Date changed from 1 Jan 2013 to 1 Dec 2015 as per ClinicalTrials.gov record.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight